IsoTag™ LV Webinar: Learn How to Design a Simplified, Cost-Effective LV Manufacturing Workflow

Webinar On-Demand by Nikki Votaw, PhD -Isolere Bio and Thomas Robert, PHD - Univercells Technologies
Presented Live on July 8th, 2025

Associate Director at Isolere Bio (part of Donaldson Life Sciences), Nikki Votaw, PhD,, and Senior Innovation and Product Manager at Univercells Technologies, Thomas Robert, PhD, share insights into combining fixed bed bioreactors and resin-free affinity purification for streamlined lentivirus manufacturing. This webinar from Donaldson Life Sciences demonstrates how these technologies deliver up to 10x higher productivity, reduce processing time by 26%, and achieve cost savings of up to 35% compared to traditional methods.

In the field of cell and gene therapy, lentiviral vector (LVV) manufacturing faces significant challenges, including high costs, scalability issues, and sensitivity to degradation. Traditional workflows often involve complex transfection processes, costly clarification steps, and inefficient downstream purification, limiting accessibility and commercial viability.

This webinar explores how the combination of scale-X™ fixed bed bioreactors (from Univercells Technologies) and IsoTag™ LVV purification reagent (from Isolere Bio) revolutionizes LVV production. Key highlights include:

Doubled upstream titers by adding IsoTag™ during bioreactor production.
26% faster processing time and 35% cost savings by eliminating clarification and nuclease steps.
Scalable and gentle purification with resin-free IsoTag™, achieving high yields (40% recovery) and purity (97% contaminant removal).
Compact, space-saving workflow fitting within a single biosafety cabinet.

Discover how this integrated approach enhances productivity, reduces costs, and simplifies manufacturing for preclinical and clinical applications.